Facial reconstruction

Search LJMU Research Online

Browse Repository | Browse E-Theses

Liposome-based dry powder vaccine immunization targeting the lungs induces broad protection against pneumococcus

Rodrigues, TC, Figueiredo, DB, Gonçalves, VM, Kaneko, K, Saleem, IY and Miyaji, EN (2024) Liposome-based dry powder vaccine immunization targeting the lungs induces broad protection against pneumococcus. Journal of Controlled Release, 368. pp. 184-198. ISSN 0168-3659

1-s2.0-S0168365924001238-main.pdf - Published Version
Available under License Creative Commons Attribution.

Download (6MB) | Preview


Streptococcus pneumoniae is an important human pathogen. Currently used conjugate vaccines are effective against invasive disease, but protection is restricted to serotypes included in the formulation, leading to serotype replacement. Furthermore, protection against non-invasive disease is reported to be considerably lower. The development of a serotype-independent vaccine is thus important and Pneumococcal surface protein A (PspA) is a promising vaccine candidate. PspA shows some diversity and can be classified in 6 clades and 3 families, with families 1 and 2 being the most frequent in clinical isolates. The ideal vaccine should thus induce protection against the two most common families of PspA. The aim of this work was to develop a liposome-based vaccine containing PspAs from family 1 and 2 and to characterize its immune response. Liposomes (LP) composed of dipalmitoylphosphatidylcholine (DPPC) and 3β-[N-(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol (DC-Chol) with or without α-galactosylceramide (α-GalCer) were produced by microfluidics, encapsulating PspA from clade 1 (PspA1, family 1) and/or clade 4 (PspA4Pro, family 2) followed by spray-drying with trehalose to form nanocomposite microparticles carriers (NCMP). LP/NCMPs showed good stability and preservation of protein activity. LP/NCMPs containing PspA1 and/or PspA4Pro were used for immunization of mice targeting the lungs. High serum IgG antibody titers against both PspA1 and PspA4Pro were detected in animals immunized with LP/NCMPs containing α-GalCer, with a balance of IgG1 and IgG2a titers. IgG in sera from immunized mice bound to pneumococcal strains from different serotypes and expressing different PspA clades, indicating broad recognition. Mucosal IgG and IgA were also detected. Importantly, immunization with LP/NCMPs induced full protection against strains expressing PspAs from family 1 and 2. Furthermore, CD4+ resident memory T cells were detected in the lungs of the immunized animals that survived the challenge.

Item Type: Article
Uncontrolled Keywords: 0903 Biomedical Engineering; 0904 Chemical Engineering; 1115 Pharmacology and Pharmaceutical Sciences; Pharmacology & Pharmacy
Subjects: Q Science > QR Microbiology > QR180 Immunology
R Medicine > RS Pharmacy and materia medica
Divisions: Pharmacy & Biomolecular Sciences
Publisher: Elsevier
SWORD Depositor: A Symplectic
Date Deposited: 26 Feb 2024 15:07
Last Modified: 26 Feb 2024 15:15
DOI or ID number: 10.1016/j.jconrel.2024.02.028
URI: https://researchonline.ljmu.ac.uk/id/eprint/22692
View Item View Item